$1.83
-0.15 (-7.58%)
Open$1.93
Previous Close$1.98
Day High$1.93
Day Low$1.69
52W High$9.50
52W Low$1.28
Volume—
Avg Volume113.0K
Market Cap66.14M
P/E Ratio—
EPS$-18.03
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,106.6% upside
Current
$1.83
$1.83
Target
$22.08
$22.08
$13.69
$22.08 avg
$22.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.10M | 11.96M | 10.98M |
| Net Income | 3.15M | 2.42M | 2.50M |
| Profit Margin | 26.0% | 20.2% | 22.8% |
| EBITDA | 4.53M | 4.37M | 3.74M |
| Free Cash Flow | 1.56M | 1.43M | 1.67M |
| Rev Growth | +0.7% | +19.7% | +24.9% |
| Debt/Equity | 0.93 | 0.73 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |